Aiming to accelerate the development of safe and effective cancer prevention drugs, the Division of Cancer Prevention is funding six chemoprevention consortia (networks of collaborative research centers) to design and implement Phase I and II clinical trials.
The Consortia aims to:
- Design and conduct early phase clinical trials to assess the cancer prevention potential of promising agents, many of which target molecules known to be evident during carcinogenesis.
- Characterize the effects of these agents on the molecular targets, as well as on other biological events associated with cancer development (such as cell proliferation, apoptosis, growth factor expression, oncogene expression) and correlate these effects with clinical endpoints.
- Develop further scientific insights into the mechanism of cancer prevention by the agent examined and continue to develop novel potential markers as determinants of response.
The Consortia are led by outstanding nationally recognized cancer research centers. Consortia members and lead investigators (listed alphabetically by state) are:
- University of Arizona, Tuscon AZ - David Alberts, M.D.
- University of California-Irvine, Irvine, CA - Frank Meyskens, M.D.
- Northwestern University, Evaston, IL - Raymond C. Bergan, M.D.
- Mayo Clinic Foundation, Rochestor MN - Paul Limburg, M.D., M.P.H.
- M. D. Anderson Cancer Center, Houston TX - Scott Lippman, M.D.
- University of Wisconsin-Madison, Madison WI - Howard Bailey, M.D.
Clinical Trials Resource Step-by-Step Instructions for Consortia Members
